These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8989422)

  • 1. The neutralization relationship of HIV type 1, HIV type 2, and SIVcpz is reflected in the genetic diversity that distinguishes them.
    Nyambi PN; Willems B; Janssens W; Fransen K; Nkengasong J; Peeters M; Vereecken K; Heyndrickx L; Piot P; van der Groen G
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):7-17. PubMed ID: 8989422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates.
    Robert-Guroff M; Aldrich K; Muldoon R; Stern TL; Bansal GP; Matthews TJ; Markham PD; Gallo RC; Franchini G
    J Virol; 1992 Jun; 66(6):3602-8. PubMed ID: 1374810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
    Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
    AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The epidemiology of simian immunodeficiency virus infection in a large number of wild- and captive-born chimpanzees: evidence for a recent introduction following chimpanzee divergence.
    Switzer WM; Parekh B; Shanmugam V; Bhullar V; Phillips S; Ely JJ; Heneine W
    AIDS Res Hum Retroviruses; 2005 May; 21(5):335-42. PubMed ID: 15929695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.
    Barbian HJ; Decker JM; Bibollet-Ruche F; Galimidi RP; West AP; Learn GH; Parrish NF; Iyer SS; Li Y; Pace CS; Song R; Huang Y; Denny TN; Mouquet H; Martin L; Acharya P; Zhang B; Kwong PD; Mascola JR; Verrips CT; Strokappe NM; Rutten L; McCoy LE; Weiss RA; Brown CS; Jackson R; Silvestri G; Connors M; Burton DR; Shaw GM; Nussenzweig MC; Bjorkman PJ; Ho DD; Farzan M; Hahn BH
    mBio; 2015 Apr; 6(2):. PubMed ID: 25900654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates.
    Beirnaert E; Nyambi P; Willems B; Heyndrickx L; Colebunders R; Janssens W; van der Groen G
    J Med Virol; 2000 Sep; 62(1):14-24. PubMed ID: 10935983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses.
    Nyambi PN; Nkengasong J; Peeters M; Simon F; Eberle J; Janssens W; Fransen K; Willems B; Vereecken K; Heyndrickx L
    J Infect Dis; 1995 Nov; 172(5):1228-37. PubMed ID: 7594658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies.
    Polonis VR; De Souza MS; Chanbancherd P; Chantakulkij S; Jugsudee A; Loomis-Price LD; Vancott TC; Garner R; Markowitz LE; Brown AE; Birx DL
    AIDS Res Hum Retroviruses; 2001 Jan; 17(1):69-79. PubMed ID: 11177385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses.
    Simon F; Souquière S; Damond F; Kfutwah A; Makuwa M; Leroy E; Rouquet P; Berthier JL; Rigoulet J; Lecu A; Telfer PT; Pandrea I; Plantier JC; Barré-Sinoussi F; Roques P; Müller-Trutwin MC; Apetrei C
    AIDS Res Hum Retroviruses; 2001 Jul; 17(10):937-52. PubMed ID: 11461679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
    Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant.
    Nyambi PN; Lewi P; Peeters M; Janssens W; Heyndrickx L; Fransen K; Andries K; Vanden Haesevelde M; Heeney J; Piot P; van der Groen G
    J Virol; 1997 Mar; 71(3):2320-30. PubMed ID: 9032368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence analysis of a highly divergent HIV-1-related lentivirus isolated from a wild captured chimpanzee.
    Vanden Haesevelde MM; Peeters M; Jannes G; Janssens W; van der Groen G; Sharp PM; Saman E
    Virology; 1996 Jul; 221(2):346-50. PubMed ID: 8661445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization of primary human immunodeficiency virus type 1 isolates: a study of parameters implicated in neutralization in vitro.
    Moog C; Spenlehauer C; Fleury H; Heshmati F; Saragosti S; Letourneur F; Kirn A; Aubertin AM
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):19-27. PubMed ID: 8989423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.